BeStock  
Stocks › Biotechnology › BBIO

BridgeBio Pharma BBIO

US equityMarket cap rank #1114Biotechnology
$76.03 −$2.15 (-2.75%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $76.03 0.00%
Open$77.85
Prev close$78.18
Day range$75.46 – $78.24
Volume1.48M
Market cap$14.81B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership100.9%+0.58 pts vs. prior quarter
Institutions holding578-2 vs. prior quarter
Insider trades (recent)26 buys / 24 sellsNet buying
Short interest10.70% of floatDays to cover 7.1 · as of 30 Oct 2026
Short-sale volume share14.0%5-day average of daily volume

Short-sale volume as % of daily volume

7%15%23%31%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$34.85M (11 inflow days, 9 outflow days).

Net flow by order size, last 20 sessions

+$34.4MSuper+$457.1KBig+$11.0MMid+$12.9MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 29.8% of shares outstanding.

Largest holders

  • Farallon Capital Management, L.L.C.7.31%
  • Janus Henderson Group plc7.24%
  • BlackRock5.33%
  • Viking Global Investors LP5.03%
  • Wellington Management Group4.86%
  • Vanguard Capital Management, LLC4.64%
  • KKR & Co. Inc.4.24%
  • Vanguard Portfolio Management, LLC3.84%

By investor type

  • Mutual Fund60.30%
  • Hedge Fund25.61%
  • VC/PE Fund7.59%
  • Individual/Insider3.95%
  • Public Company3.16%
  • Private Company2.05%
  • Sovereign Wealth Fund0.87%
  • Government Pension Fund0.67%

Reported short interest has fallen from 11.93% to 10.70% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Wellington Management Group Mutual Fund 2026/Q4 +4,150,068 4.9%
Farallon Capital Management, L.L.C. Hedge Fund 2026/Q4 +3,503,937 7.3%
Paradigm Biocapital Advisors LP Hedge Fund 2026/Q4 +2,347,850 1.2%
J.P. Morgan Asset Management, Inc. Mutual Fund 2026/Q4 +1,719,092 1.9%
Franklin Resources Mutual Fund 2026/Q4 +1,118,756 1.7%
Deep Track Capital, LP VC/PE Fund 2026/Q4 +885,882 0.5%
Hartford Funds Management Company, LLC Mutual Fund 2026/Q4 +817,133 0.5%
AQR Capital Management Hedge Fund 2026/Q4 +815,677 0.5%
Citigroup Inc. Public Company 2026/Q4 +812,362 0.9%
UBS Asset Management Mutual Fund 2026/Q4 +805,312 1.6%
Adage Capital Management, L.P. Hedge Fund 2026/Q4 +779,958 1.6%
PRIMECAP Management Company Mutual Fund 2026/Q4 +683,442 0.9%
Invesco Ltd. Mutual Fund 2026/Q4 +611,527 2.1%
State Street Global Advisors Mutual Fund 2026/Q4 +541,227 2.6%
Candriam, Société En Commandite Par Actions Mutual Fund 2026/Q4 +402,325 0.4%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
29 Oct 2026 Maricel Apuli Chief Accounting Officer Automatic Disposition -2,000 $72.85 120,687
16 Sep 2026 Neil Kumar Chief Executive Officer Automatic Disposition -10,000 $69.57 5,057,460
18 Aug 2026 Neil Kumar Chief Executive Officer Automatic Disposition -44,980 $85.65 5,067,460
17 Aug 2026 Neil Kumar Chief Executive Officer Intent to Sell (Form 144) -34,980 $79.89 –
16 Aug 2026 Randal Scott Former Independent Director Intent to Sell (Form 144) -21,501 $79.86 –
15 Aug 2026 Neil Kumar Chief Executive Officer Derivative Exercise and Sale -36,237 $79.86 5,112,440
15 Aug 2026 Neil Kumar Chief Executive Officer Derivative Exercise and Retained +34,980 – 5,112,440
15 Aug 2026 Thomas Trimarchi CFO & President Sale to Issuer -22,781 $79.86 336,529
15 Aug 2026 Maricel Apuli Chief Accounting Officer Sale to Issuer -4,714 $79.86 122,687
29 Jul 2026 Maricel Apuli Chief Accounting Officer Automatic Disposition -2,000 $80.06 127,401
8 Jul 2026 Jennifer Cook Independent Director Derivative Exercise and Sale -148,589 $90.00 8,383
8 Jul 2026 Andrea Ellis Independent Director Derivative Exercise and Sale -17,167 $84.00 14,196
23 Jun 2026 Randal Scott Former Independent Director Intent to Sell (Form 144) -2,196 $68.63 –
23 Jun 2026 Jennifer Cook Independent Director Derivative Exercise and Sale -37,167 $70.00 –
22 Jun 2026 Jennifer Cook Independent Director Automatic Disposition -2,196 $68.57 –
22 Jun 2026 Hannah Valantine Independent Director Automatic Disposition -2,196 $68.57 1,274
21 Jun 2026 Charles Homcy Co-Founder, Chairman of Pharmaceuticals & Lead Director Other Acquisition +3,990 – 8,383
21 Jun 2026 Charles Homcy Co-Founder, Chairman of Pharmaceuticals & Lead Director Other Derivative Acquisition +5,277 $68.92 5,277
21 Jun 2026 Fred Hassan Lead Independent Director Other Acquisition +3,990 – 8,383
21 Jun 2026 Fred Hassan Lead Independent Director Other Derivative Acquisition +5,277 $68.92 5,277

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 20,846,164 10.7% 7.1
15 Oct 2026 19,997,556 10.2% 7.7
30 Sep 2026 19,671,292 10.1% 5.9
15 Sep 2026 21,549,349 11.0% 10.5
31 Aug 2026 21,845,899 11.2% 11.2
14 Aug 2026 23,324,059 11.9% 10.8

Discussion

No comments yet — be the first to weigh in on BBIO.

Sign in to join the discussion.

Scroll to Top